MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtcvs.2016.12.048

Медицинская библиотека · The Journal of thoracic and cardiovascular surgery · 2017

Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer.

Czarnecka-Kujawa Katarzyna, Rochau Ursula, Siebert Uwe, Atenafu Eshetu, Darling Gail, Waddell Thomas Kenneth, Pierre Andrew, De Perrot Marc, Cypel Marcelo, Keshavjee Shaf, Yasufuku Kazuhiro

СтатьяКомментарийПеревод пока не подготовлен

Аннотация

OBJECTIVE

To assess the cost-effectiveness of various modes of mediastinal staging in non-small cell lung cancer (NSCLC) in a single-payer health care system.

METHODS

We performed a decision analysis to compare the health outcomes and costs of 4 mediastinal staging strategies: no invasive staging, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), mediastinoscopy, and EBUS-TBNA followed by mediastinoscopy if EBUS-TBNA is negative. We determined incremental cost effectiveness ratios (ICER) for all strategies and performed comprehensive deterministic sensitivity analyses using a willingness to pay threshold of $80,000/quality adjusted life year (QALY).

RESULTS

Under the base-case scenario, the no invasive mediastinal staging strategy was least effective (QALY, 5.80) and least expensive ($11,863), followed by mediastinoscopy, EBUS-TBNA, and EBUS-TBNA followed by mediastinoscopy with 5.86, 5.87, and 5.88 QALYs, respectively. The ICER was ∼$26,000/QALY for EBUS-TBNA staging and ∼$1,400,000/QALY for EBUS-TBNA followed by mediastinoscopy. The mediastinoscopy strategy was dominated. Once pN2 exceeds 2.5%, EBUS-TBNA staging is cost-effective (∼$80,000/QALY). Once the pN2 reaches 57%, EBUS-TBNA followed by mediastinoscopy is cost-effective (ICER ∼$79,000/QALY). Once EBUS-TBNA sensitivity exceeds 25%, EBUS-TBNA staging is cost-effective (ICER ∼$79,000/QALY). Once pN2 exceeds 25%, confirmatory mediastinoscopy should be added, in cases of EBUS-TBNA sensitivity ≤ 60%.

CONCLUSIONS

Invasive mediastinal staging in NSCLC is unlikely to be cost-effective in clinical N0 patients if pN2 <2.5%. In patients with probability of mediastinal metastasis between 2.5% and 57% EBUS-TBNA is cost-effective as the only staging modality. Confirmatory mediastinoscopy should be considered in high-risk patients (pN2 > 57%) in case of negative EBUS-TBNA.

Для цитирования: Czarnecka-Kujawa Katarzyna, Rochau Ursula, Siebert Uwe, Atenafu Eshetu, Darling Gail, Waddell Thomas Kenneth, Pierre Andrew, De Perrot Marc, Cypel Marcelo, Keshavjee Shaf, Yasufuku Kazuhiro. Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer.. The Journal of thoracic and cardiovascular surgery. 2017. DOI: 10.1016/j.jtcvs.2016.12.048.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.